{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T22:21:19Z","timestamp":1781907679167,"version":"3.54.5"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011755","name":"National Center for Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008306","name":"Uniwersytet Wroc\u0142awski","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"National Centre for Research and Development","doi-asserted-by":"publisher","award":["ERA-NET-E-RARE-3\/III\/TREARHGPS"],"award-info":[{"award-number":["ERA-NET-E-RARE-3\/III\/TREARHGPS"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102727","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:26:58Z","timestamp":1759548418000},"page":"102727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Selection of specific and efficient siRNAs in new cellular model for Hutchinson-Gilford progeria syndrome therapy"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-2246","authenticated-orcid":false,"given":"Volha","family":"Dzianisava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Piekarowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Machowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2582-3965","authenticated-orcid":false,"given":"Ryszard","family":"Rzepecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102727_bib1","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1091\/mbc.11.12.4323","article-title":"Head and\/or CaaX Domain Deletions of Lamin Proteins Disrupt Preformed Lamin A and C But Not Lamin B Structure in Mammalian Cells","volume":"11","author":"Izumi","year":"2000","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omtn.2025.102727_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1474-9726.2008.00382.x","article-title":"Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors","volume":"7","author":"Verstraeten","year":"2008","journal-title":"Aging Cell"},{"key":"10.1016\/j.omtn.2025.102727_bib3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1083\/jcb.200904124","article-title":"Role of A-type lamins in signaling, transcription, and chromatin organization","volume":"187","author":"Andr\u00e9s","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102727_bib4","first-page":"11709","article-title":"Lamin A\/C promotes DNA base excision repair","volume":"47","author":"Maynard","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102727_bib5","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1126\/science.1084125","article-title":"Lamin a truncation in Hutchinson-Gilford progeria","volume":"300","author":"De Sandre-Giovannoli","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102727_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature01629","article-title":"Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome","volume":"423","author":"Eriksson","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102727_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/cells8020088","article-title":"Hutchinson-Gilford Progeria Syndrome\u2014Current Status and Prospects for Gene Therapy Treatment","volume":"8","author":"Piekarowicz","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102727_bib8","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2406946121","article-title":"Progerin forms an abnormal meshwork and has a dominant-negative effect on the nuclear lamina","volume":"121","author":"Kim","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102727_bib9","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.jid.2019.05.005","article-title":"Accumulation of Progerin Affects the Symmetry of Cell Division and Is Associated with Impaired Wnt Signaling and the Mislocalization of Nuclear Envelope Proteins","volume":"139","author":"Sola-Carvajal","year":"2019","journal-title":"Invest. Dermatol."},{"key":"10.1016\/j.omtn.2025.102727_bib10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCULATIONAHA.117.030856","article-title":"Vascular smooth muscle\u2013specific progerin expression accelerates atherosclerosis and death in a mouse model of Hutchinson-Gilford progeria syndrome","volume":"138","author":"Hamczyk","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102727_bib11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3390\/cells10051157","article-title":"Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models","volume":"10","author":"Benedicto","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102727_bib12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41419-024-06863-8","article-title":"mtDNA release promotes cGAS-STING activation and accelerated aging of postmitotic muscle cells","volume":"15","author":"Li","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2025.102727_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011132","article-title":"Defective Lamin A-Rb Signaling in Hutchinson-Gilford Progeria Syndrome and Reversal by Farnesyltransferase Inhibition","volume":"5","author":"Marji","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102727_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-92631-z","article-title":"Progerin impairs 3D genome organization and induces fragile telomeres by limiting the dNTP pools","volume":"11","author":"Kychygina","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102727_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13108","article-title":"Heterochromatin loss as a determinant of progerin-induced DNA damage in Hutchinson\u2013Gilford Progeria","volume":"19","author":"Chojnowski","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.omtn.2025.102727_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0315084","article-title":"Progerin can induce DNA damage in the absence of global changes in replication or cell proliferation","volume":"19","author":"Joudeh","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102727_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2023.103491","article-title":"Corruption of DNA end-joining in mammalian chromosomes by progerin expression","volume":"126","author":"Joudeh","year":"2023","journal-title":"DNA Repair"},{"key":"10.1016\/j.omtn.2025.102727_bib18","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1242\/jcs.03263","article-title":"DNA Damage Responses in Progeroid Syndromes Arising from Defective Maturation of Prelamin A","volume":"119","author":"Liu","year":"2006","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omtn.2025.102727_bib19","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309200120","article-title":"Impaired end joining induces cardiac atrophy in a Hutchinson\u2013Gilford progeria mouse model","volume":"120","author":"Chen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102727_bib20","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/hmg\/ddi326","article-title":"Incomplete processing of mutant lamin A in Hutchinson\u2013Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition","volume":"14","author":"Glynn","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102727_bib21","doi-asserted-by":"crossref","first-page":"8963","DOI":"10.1073\/pnas.0402943101","article-title":"Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson\u2013Gilford progeria syndrome","volume":"101","author":"Goldman","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102727_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJMoa0706898","article-title":"Phenotype and Course of Hutchinson\u2013Gilford Progeria Syndrome","volume":"358","author":"Merideth","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102727_bib23","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1161\/CIRCULATIONAHA.122.060002","article-title":"Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation","volume":"147","author":"Gordon","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102727_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.0b013e31829d85c0","article-title":"Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment","volume":"81","author":"Ullrich","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2025.102727_bib25","doi-asserted-by":"crossref","first-page":"16666","DOI":"10.1073\/pnas.1202529109","article-title":"Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome","volume":"109","author":"Gordon","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102727_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.116.022188","article-title":"Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome","volume":"134","author":"Gordon","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.omtn.2025.102727_bib27","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nm1786","article-title":"Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging","volume":"14","author":"Varela","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102727_bib28","doi-asserted-by":"crossref","first-page":"64809","DOI":"10.18632\/oncotarget.19363","article-title":"Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts","volume":"8","author":"Gabriel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2025.102727_bib29","doi-asserted-by":"crossref","first-page":"29914","DOI":"10.18632\/oncotarget.4939","article-title":"All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype","volume":"6","author":"Pellegrini","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2025.102727_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002346","article-title":"Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells","volume":"3","author":"Cao","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102727_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41591-018-0338-6","article-title":"Development of a CRISPR\/Cas9-based therapy for Hutchinson\u2013Gilford progeria syndrome","volume":"25","author":"Santiago-Fern\u00e1ndez","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102727_bib32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","article-title":"In Vivo Base Editing Rescues Hutchinson-Gilford Progeria Syndrome in Mice","volume":"589","author":"Koblan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102727_bib33","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1016\/j.ymthe.2025.06.017","article-title":"Precise Progerin Targeting Using RfxCas13d: A Therapeutic Avenue for Hutchinson\u2013Gilford Progeria Syndrome","volume":"33","author":"Chae","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102727_bib34","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00439-005-0051-7","article-title":"Correction of cellular phenotypes of Hutchinson-Gilford Progeria cells by RNA interference","volume":"118","author":"Huang","year":"2005","journal-title":"Hum. Genet."},{"key":"10.1016\/j.omtn.2025.102727_bib35","doi-asserted-by":"crossref","first-page":"9122","DOI":"10.1038\/s41598-021-88325-1","article-title":"Human WRN is an intrinsic inhibitor of progerin, abnormal splicing product of lamin A","volume":"11","author":"Kang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102727_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12991","article-title":"Sirtuin 1 ameliorates defenestration in hepatic sinusoidal endothelial cells during liver fibrosis via inhibiting stress-induced premature senescence","volume":"54","author":"Luo","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.omtn.2025.102727_bib37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nm1204","article-title":"Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome","volume":"11","author":"Scaffidi","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102727_bib38","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41591-021-01274-0","article-title":"A targeted antisense therapeutic approach for Hutchinson\u2013Gilford progeria syndrome","volume":"27","author":"Erdos","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102727_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002847","article-title":"Splicing-directed therapy in a new mouse model of human accelerated aging","volume":"3","author":"Osorio","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102727_bib40","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41591-021-01262-4","article-title":"Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson\u2013Gilford progeria syndrome","volume":"27","author":"Puttaraju","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2025.102727_bib41","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1073\/pnas.0600012103","article-title":"Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome","volume":"103","author":"Varga","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102727_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.yexcr.2003.07.002","article-title":"Nuclear envelope alterations in fibroblasts from LGMD1B patients carrying nonsense Y259X heterozygous or homozygous mutation in lamin A\/C gene","volume":"291","author":"Muchir","year":"2003","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omtn.2025.102727_bib43","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2400752121","article-title":"Exacerbated atherosclerosis in progeria is prevented by progerin elimination in vascular smooth muscle cells but not endothelial cells","volume":"121","author":"Benedicto","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102727_bib44","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1073\/pnas.0611640104","article-title":"A lamin A protein isoform overexpressed in Hutchinson-Gilford progeria syndrome interferes with mitosis in progeria and normal cells","volume":"104","author":"Cao","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102727_bib45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-0774.2009.00066.x","article-title":"Donor age reflects the replicative lifespan of human fibroblasts in culture","volume":"22","author":"Kaji","year":"2009","journal-title":"Hum. Cell"},{"key":"10.1016\/j.omtn.2025.102727_bib46","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.3390\/cells11182784","article-title":"Establishment and Characterization of hTERT Immortalized Hutchinson\u2013Gilford Progeria Fibroblast Cell Lines","volume":"11","author":"Lin","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102727_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fcell.2018.00172","article-title":"Induced Pluripotent Stem Cells to Study Mechanisms of Laminopathies: Focus on Epigenetics","volume":"6","author":"Crasto","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2025.102727_bib48","article-title":"Nuclear envelope budding inhibition slows down progerin-induced aging process","volume":"121","author":"Wang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102727_bib49","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/ncb1708","article-title":"Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing","volume":"10","author":"Scaffidi","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102727_bib50","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2741\/216","article-title":"A-type lamins and Hutchinson-Gilford progeria syndrome: pathogenesis and therapy","volume":"3","author":"Gonzalez","year":"2011","journal-title":"Front. Biosci. (Schol. Ed.)"},{"key":"10.1016\/j.omtn.2025.102727_bib51","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: State-of-the-Art and Future Perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.omtn.2025.102727_bib52","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.bbrc.2004.02.157","article-title":"An algorithm for selection of functional siRNA sequences","volume":"316","author":"Amarzguioui","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2025.102727_bib53","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/nar\/gkh247","article-title":"Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference","volume":"32","author":"Ui-Tei","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102727_bib54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nbt936","article-title":"Rational siRNA design for RNA interference","volume":"22","author":"Reynolds","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102727_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/d41573-021-00168-7","article-title":"The FDA approves a first farnesyltransferase inhibitor","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102727_bib56","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.omtn.2025.102727_bib57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/cgt.2016.4","article-title":"Precise and efficient siRNA design: A key point in competent gene silencing","volume":"23","author":"Fakhr","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omtn.2025.102727_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115321","article-title":"A current overview of RhoA, RhoB, and RhoC functions in vascular biology and pathology","volume":"206","author":"Eckenstaler","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102727_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049309","article-title":"siRNA Has Greatly Elevated Mismatch Tolerance at 3\u2032-UTR Sites","volume":"7","author":"Wei","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102727_bib60","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nbt1404","article-title":"The impact of target site accessibility on the design of effective siRNAs","volume":"26","author":"Tafer","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2025.102727_bib61","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5966\/sctm.2013-0168","article-title":"Induced Pluripotent Stem Cells Reveal Functional Differences Between Drugs Currently Investigated in Patients With Hutchinson-Gilford Progeria Syndrome","volume":"3","author":"Blondel","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.omtn.2025.102727_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2012.05.015","article-title":"Unique preservation of neural cells in hutchinson- gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA","volume":"2","author":"Nissan","year":"2012","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2025.102727_bib63","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.stem.2011.04.019","article-title":"Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs","volume":"8","author":"Liu","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtn.2025.102727_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.374","article-title":"Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation","volume":"7","author":"Blondel","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2025.102727_bib65","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.bpj.2020.04.001","article-title":"Chromatin and Cytoskeletal Tethering Determine Nuclear Morphology in Progerin-Expressing Cells","volume":"118","author":"Lionetti","year":"2020","journal-title":"Biophys. J."},{"key":"10.1016\/j.omtn.2025.102727_bib66","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1016\/j.jbiomech.2008.08.024","article-title":"Nuclear mechanotransduction: Response of the lamina to extracellular stress with implications in aging","volume":"41","author":"Philip","year":"2008","journal-title":"J. Biomech."},{"key":"10.1016\/j.omtn.2025.102727_bib67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/cells10010153","article-title":"Nuclear Pore Complexes Cluster in Dysmorphic Nuclei of Normal and Progeria Cells during Replicative Senescence","volume":"10","author":"R\u00f6hrl","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102727_bib68","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1126\/science.1199784","article-title":"Proteome Half-Life Dynamics in Living Human Cells","volume":"331","author":"Eden","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102727_bib69","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/19491034.2016.1260803","article-title":"Comparing lamin proteins post-translational relative stability using a 2A peptide-based system reveals elevated resistance of progerin to cellular degradation","volume":"7","author":"Wu","year":"2016","journal-title":"Nucleus"},{"key":"10.1016\/j.omtn.2025.102727_bib70","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejcb.2018.01.002","article-title":"Overexpression of the lamina proteins Lamin and Kugelkern induces specific ultrastructural alterations in the morphology of the nuclear envelope of intestinal stem cells and enterocytes","volume":"97","author":"Petrovsky","year":"2018","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102727_bib71","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.256156","article-title":"A lamin A\/C variant causing striated muscle disease provides insights into filament organization","volume":"134","author":"Kronenberg-Tenga","year":"2021","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omtn.2025.102727_bib72","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1242\/jcs.01532","article-title":"The lamin CxxM motif promotes nuclear membrane growth","volume":"117","author":"Pr\u00fcfert","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omtn.2025.102727_bib73","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1242\/jcs.01528","article-title":"Intranuclear membrane structure formations by CaaX-containing nuclear proteins","volume":"117","author":"Ralle","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omtn.2025.102727_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032649","article-title":"The different function of single phosphorylation sites of drosophila melanogaster lamin Dm and lamin C","volume":"7","author":"Zaremba-Czogalla","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102727_bib75","article-title":"The nucleus bypasses obstacles by deforming like a drop with surface tension mediated by lamin A\/C","volume":"9","author":"Katiyar","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.omtn.2025.102727_bib76","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.248559","article-title":"Spatial distribution of lamin A\/C determines nuclear stiffness and stress-mediated deformation","volume":"134","author":"Srivastava","year":"2021","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.omtn.2025.102727_bib77","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/humu.20536","article-title":"Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes","volume":"28","author":"Moulson","year":"2007","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2025.102727_bib78","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1172\/JCI27125","article-title":"Prelamin A and lamin A appear to be dispensable in the nuclear lamina","volume":"116","author":"Fong","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102727_bib79","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2353\/ajpath.2006.050564","article-title":"Emerin-lacking mice show minimal motor and cardiac dysfunctions with nuclear-associated vacuoles","volume":"168","author":"Ozawa","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omtn.2025.102727_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221512","article-title":"Deficiency of emerin contributes differently to the pathogenesis of skeletal and cardiac muscles in LmnaH222P\/H222P mutant mice","volume":"14","author":"Wada","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102727_bib81","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12576-023-00886-0","article-title":"Emerin deficiency does not exacerbate cardiomyopathy in a murine model of Emery-Dreifuss muscular dystrophy caused by an LMNA gene mutation","volume":"73","author":"Wada","year":"2023","journal-title":"J. Physiol. Sci."},{"key":"10.1016\/j.omtn.2025.102727_bib82","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/B978-0-444-59565-2.00007-1","article-title":"Emery-Dreifuss muscular dystrophy, laminopathies, and other nuclear envelopathies","volume":"113","author":"Bonne","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.omtn.2025.102727_bib83","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1124875","article-title":"A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria","volume":"311","author":"Fong","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102727_bib84","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1001\/jama.2018.3264","article-title":"Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome","volume":"319","author":"Gordon","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102727_bib85","unstructured":"ClinicalTrials.gov. A Study to Evaluate Safety and Efficacy of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (NCT06775041). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06775041."},{"key":"10.1016\/j.omtn.2025.102727_bib86","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1172\/JCI85908","article-title":"Modulation of LMNA splicing as a strategy to treat prelamin A diseases","volume":"126","author":"Lee","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omtn.2025.102727_bib87","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/nprot.2007.278","article-title":"A protocol for designing siRNAs with high functionality and specificity","volume":"2","author":"Birmingham","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtn.2025.102727_bib88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fgene.2012.00101","article-title":"Thermodynamic control of small RNA-mediated gene silencing","volume":"3","author":"Ui-Tei","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.omtn.2025.102727_bib89","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-019-0084-z","article-title":"Generation and characterization of a novel knockin minipig model of Hutchinson-Gilford progeria syndrome","volume":"5","author":"Dorado","year":"2019","journal-title":"Cell Discov."},{"key":"10.1016\/j.omtn.2025.102727_bib90","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.omtn.2025.102727_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","article-title":"ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy","volume":"8","author":"Ottesen","year":"2017","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.omtn.2025.102727_bib92","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.56","article-title":"Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model","volume":"5","author":"Perepelyuk","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102727_bib93","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1261\/rna.5103703","article-title":"siRNA function in RNAi: A chemical modification analysis","volume":"9","author":"Chiu","year":"2003","journal-title":"RNA (New York, N.Y.)"},{"key":"10.1016\/j.omtn.2025.102727_bib94","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.2008.0123","article-title":"Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs","volume":"18","author":"Collingwood","year":"2008","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.omtn.2025.102727_bib95","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1021\/jm050044o","article-title":"Positional effect of chemical modifications on short interference RNA activity in mammalian cells","volume":"48","author":"Prakash","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omtn.2025.102727_bib96","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1093\/nar\/gkg393","article-title":"Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells","volume":"31","author":"Czauderna","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102727_bib97","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbrc.2006.02.049","article-title":"Chemical modification of siRNAs to improve serum stability without loss of efficacy","volume":"342","author":"Choung","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omtn.2025.102727_bib98","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1021\/acsomega.7b00291","article-title":"Chemical Modification of the siRNA Seed Region Suppresses Off-Target Effects by Steric Hindrance to Base-Pairing with Targets","volume":"2","author":"Iribe","year":"2017","journal-title":"ACS Omega"},{"key":"10.1016\/j.omtn.2025.102727_bib99","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.omtm.2019.09.001","article-title":"A Muscle Hybrid Promoter as a Novel Tool for Gene Therapy","volume":"15","author":"Piekarowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102727_bib100","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14712\/fb2006052030059","article-title":"NORs and their transcription competence during the cell cycle","volume":"52","author":"Smirnov","year":"2006","journal-title":"Folia Biol."},{"key":"10.1016\/j.omtn.2025.102727_bib101","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.omtn.2025.102727_bib102","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2105-11-129","article-title":"RNAstructure: Software for RNA secondary structure prediction and analysis","volume":"11","author":"Reuter","year":"2010","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.omtn.2025.102727_bib103","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1748-7188-6-26","article-title":"ViennaRNA Package 2.0","volume":"6","author":"Lorenz","year":"2011","journal-title":"Algorithms Mol. Biol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125002811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125002811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T02:10:22Z","timestamp":1766196622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125002811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125002811"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102727","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection of specific and efficient siRNAs in new cellular model for Hutchinson-Gilford progeria syndrome therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102727"}}